about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

From hours to min­utes? Genen­tech says Ocre­vus sub­cu­ta­neous for­mu­la­tion works just as well as IV

Last year
R&D

Bio­Gen­er­a­tion Ven­tures clos­es $167M fund to hatch Eu­ro­pean star­tups with back­ing from Eli Lil­ly, No­vo, BMS

Last year
Financing
Startups

In­cyte says JAK cream clears PhI­II eczema tri­al in chil­dren, but an­a­lysts are still watch­ing safe­ty

Last year
R&D
Pharma

WuXi Bi­o­log­ics seeks spin­out, HK list­ing of bio­con­ju­gates-fo­cused joint ven­ture

Last year
Financing
China

Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; ...

Last year
Weekly

Brii Bio­sciences snaps up VBI Vac­ci­nes' HBV pro­grams in ex­pand­ed deal, jump­ing in­to com­mer­cial mode

Last year
Deals

FDA re­jects Am­neal's ex­tend­ed-re­lease Parkin­son's treat­ment, seek­ing more safe­ty da­ta

Last year
FDA+

As­traZeneca, Dai­ichi Sankyo claim PhI­II lung can­cer win for their next big ADC — but shares fall

Last year
R&D

Cell ther­a­py for di­a­betes: New da­ta, ap­proval, buy­out; GLP-1 race in weight loss reach­es new stage; FDA fi­nal­ly ...

Last year
Weekly

Bellerophon Ther­a­peu­tics lets al­most all em­ploy­ees go, looks for deals in wake of PhI­II flop

Last year
People

Tout­ing pro­grams from No­var­tis, Laek­na bags $100M in Hong Kong IPO while Mer­ck-part­nered Kelun seeks up to $208M

Last year
Financing
China

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Last year
R&D
Pharma

Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Last year
R&D

Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Last year
R&D
Cell/Gene Tx

Top drug from Sanofi’s $1.5B Kymab buy­out aces PhI­Ib in eczema

Last year
R&D

Af­ter steer­ing Lund­beck through buy­outs, lay­offs and big ap­proval, Deb­o­rah Dun­sire will step down

Last year
People

Sh­iono­gi takes an­tibi­ot­ic mak­er un­der its wing in $100M cash buy­out

Last year
Deals

Sarep­ta's Duchenne gene ther­a­py wins OK; FDA spurns NASH drug; Eli Lil­ly buys DICE for $2.4B; The new an­titrust ...

Last year
Weekly

LA­VA Ther­a­peu­tics winds down bis­pe­cif­ic tri­al; Blue Wa­ter buys six mar­ket­ed drugs for $8.5M

Last year
News Briefing

Bio­gen lines up po­ten­tial deal for ALS drug, dou­bling down on neu­ro­fil­a­ment bio­mark­er

Last year
Deals

Ery­tech blasts ac­tivist in­vestor's at­tempt to block re­verse merg­er, Akka­di­an pro­pos­es new board in re­turn

Last year
People
Deals

No­var­tis adds $3.2B cash deal to M&A tal­ly, snap­ping up Chi­nook and its late-stage kid­ney drugs

Last year
Deals
Pharma

Ad­comm votes yes on Leqem­bi full OK; Mer­ck brings first IRA law­suit; Spe­cial: LGBTQ+ lead­ers; Best-pay­ing bio­phar­ma ...

Last year
Weekly

Disc Med­i­cine claims PhII win for re­pur­posed ex-Roche drug in rare blood dis­or­der

Last year
R&D
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times